Rock Springs Capital Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Rock Springs Capital Management’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-43,445	Closed	-$242K	–	132
2015 Q4	$242K	Sell	43,445 -441,555	-91%	-$2.92M	0.02%	120
2015 Q3	$4.1M	Buy	485,000 +185,000	+62%	+$3.13M	0.33%	92
2015 Q2	$4.54M	Buy	+300,000	New	+$4.33M	0.33%	94

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

MAM

MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Rock Springs Capital Management's PETX Position: Q1 2016 in Review

Rock Springs Capital Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2016, closing a stake of 43,445 shares — an estimated $242K sold.

Rock Springs Capital Management first reported a position in PETX in Q2 2015 and held it in 3 quarters. The position peaked at $4.54M in Q2 2015. 95 funds tracked by Wall St. Rank hold PETX as of Q1 2016.

Rock Springs Capital Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2016 after selling out during the quarter.
Rock Springs Capital Management sold 43,445 Aratana Therapeutics, Inc. shares in Q1 2016, an estimated $242K.
Rock Springs Capital Management first reported a position in Aratana Therapeutics, Inc. in Q2 2015 and held it in 3 quarters.
Rock Springs Capital Management's Aratana Therapeutics, Inc. position peaked at $4.54M in Q2 2015.
95 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2016.

Based on Rock Springs Capital Management's 13F filing for Q1 2016, filed 16 May 2016.